ATE517866T1 - Spiropiperidinderivate - Google Patents

Spiropiperidinderivate

Info

Publication number
ATE517866T1
ATE517866T1 AT07857529T AT07857529T ATE517866T1 AT E517866 T1 ATE517866 T1 AT E517866T1 AT 07857529 T AT07857529 T AT 07857529T AT 07857529 T AT07857529 T AT 07857529T AT E517866 T1 ATE517866 T1 AT E517866T1
Authority
AT
Austria
Prior art keywords
spiropiperidine derivatives
spiropiperidine
derivatives
Prior art date
Application number
AT07857529T
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Raffaello Masciadri
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301516&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517866(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE517866T1 publication Critical patent/ATE517866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
AT07857529T 2006-12-22 2007-12-13 Spiropiperidinderivate ATE517866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127078 2006-12-22
PCT/EP2007/063882 WO2008077811A1 (en) 2006-12-22 2007-12-13 Spiro-piperidine derivatives

Publications (1)

Publication Number Publication Date
ATE517866T1 true ATE517866T1 (de) 2011-08-15

Family

ID=39301516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07857529T ATE517866T1 (de) 2006-12-22 2007-12-13 Spiropiperidinderivate

Country Status (18)

Country Link
US (3) US7678806B2 (de)
EP (1) EP2125726B1 (de)
JP (1) JP2010513385A (de)
KR (1) KR101122969B1 (de)
CN (1) CN101563323B (de)
AR (1) AR064480A1 (de)
AT (1) ATE517866T1 (de)
AU (1) AU2007338116B2 (de)
BR (1) BRPI0720845A2 (de)
CA (1) CA2674518A1 (de)
CL (1) CL2007003719A1 (de)
ES (1) ES2370047T3 (de)
MX (1) MX2009006446A (de)
NO (1) NO20092264L (de)
PE (1) PE20081486A1 (de)
RU (1) RU2009123134A (de)
TW (1) TWI339663B (de)
WO (1) WO2008077811A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513385A (ja) * 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8916565B2 (en) * 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
NO3083633T3 (de) * 2013-12-19 2018-04-28
CN104557777B (zh) * 2015-01-09 2016-08-31 万华化学集团股份有限公司 一种n-甲基哌嗪的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450761A1 (de) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclische Oxtocin-Antagonisten
CA2143117A1 (en) * 1992-10-07 1994-04-14 Ben E. Evans Tocolytic oxytocin receptor antagonists
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
DE60115092T2 (de) 2000-12-12 2006-03-30 Neurogen Corp., Brandford Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
MXPA04004982A (es) 2001-11-27 2004-08-11 Hoffmann La Roche Derivados de benzotiazol.
AU2004309164B2 (en) * 2003-12-22 2007-11-15 Pfizer Inc. Triazole derivatives as vasopressin antagonists
JP2010513385A (ja) * 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体

Also Published As

Publication number Publication date
US20080167333A1 (en) 2008-07-10
CA2674518A1 (en) 2008-07-03
US20080280898A1 (en) 2008-11-13
US20080161304A1 (en) 2008-07-03
US7495008B2 (en) 2009-02-24
EP2125726B1 (de) 2011-07-27
NO20092264L (no) 2009-06-24
EP2125726A1 (de) 2009-12-02
AU2007338116A1 (en) 2008-07-03
TW200833696A (en) 2008-08-16
RU2009123134A (ru) 2011-01-27
WO2008077811A1 (en) 2008-07-03
BRPI0720845A2 (pt) 2014-03-04
CN101563323A (zh) 2009-10-21
PE20081486A1 (es) 2008-10-18
US7501432B2 (en) 2009-03-10
US7678806B2 (en) 2010-03-16
CN101563323B (zh) 2012-07-04
AU2007338116B2 (en) 2012-04-26
JP2010513385A (ja) 2010-04-30
KR101122969B1 (ko) 2012-03-22
MX2009006446A (es) 2009-06-26
AR064480A1 (es) 2009-04-01
CL2007003719A1 (es) 2008-07-11
ES2370047T3 (es) 2011-12-12
KR20090082505A (ko) 2009-07-30
TWI339663B (en) 2011-04-01

Similar Documents

Publication Publication Date Title
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
ATE486877T1 (de) Azaspiroderivate
BRPI0813836A2 (pt) Derivados pirazólicos
ATE518837T1 (de) Indazolamidderivate
BRPI0814236A2 (pt) Derivados de quinazolinamida
AT504580A3 (de) Scan-einrichtung
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
ATE546437T1 (de) Aminomethyl-4-imidazole
DK2152370T3 (da) Aryletherpyridazinonderivater
ATE536356T1 (de) Spiropiperidin-glycinamid-derivate
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
ATE469899T1 (de) Spiropiperidinderivate
ATE519760T1 (de) Isoxazolimidazolderivate
DE602007001593D1 (de) Aryl-/alkylvinylsulfon-hyaluronsäurederivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2125726

Country of ref document: EP